がん生物学的療法市場：製品、投与経路、エンドユーザー別-2025-2030年の世界予測

がん生物学的療法市場は、2023年に649億5,000万米ドルと評価され、2024年には724億2,000万米ドルに達すると予測され、CAGR 11.60％で成長し、2030年には1,400億4,000万米ドルになると予測されています。

免疫療法として知られるがん生物学的療法は、モノクローナル抗体、ワクチン、サイトカイン療法のような様々な方法を包含し、がん細胞を標的にして闘うために身体の免疫システムを活用します。がんの罹患率が上昇を続けるなか、化学療法や放射線療法といった従来の方法よりも副作用の少ない革新的な治療法の必要性が高まっています。この生物学的に多様な治療アプローチは、メラノーマ、乳がん、白血病など、数多くのがん種に重要な応用が可能です。最終用途の範囲には、主に病院、専門のがん治療センター、研究機関が含まれ、そこでは患者固有のがんプロファイルに基づいてオーダーメイドの生物学的療法を開発することができます。

市場の成長は、生物製剤のパイプラインの拡大や規制当局による承認の増加に加え、バイオテクノロジーの技術的進歩やがんゲノミクスのより深い理解によって大きく左右されます。潜在的なビジネスチャンスは、個別化医療に対する需要の高まりと、これまで治療が困難であったがんに対応する新しい治療法の急速な開発にあります。これを活用するため、企業は次世代抗体薬物複合体や細胞ベースの免疫療法の研究開発に投資する必要があります。しかし、この市場は高い治療費、複雑な製造工程、厳しい規制要件といった課題に直面しており、これが商業化を遅らせる要因となっています。

有効性と患者の利便性を向上させるためにドラッグデリバリーシステムを強化し、個別化治療レジメンのために人工知能の利用を模索することで、イノベーションを推進することができます。バイオシミラーや新規バイオマーカーを開発するための研究機関との共同研究は、市場の成長をさらに促進する可能性があります。市場は依然としてダイナミックで、絶え間ないブレークスルーが見られるが、競争力を維持するためには、企業は規制状況を巧みに操り、コスト障壁を管理する必要があります。これらの戦略に注力することで、企業は新たな動向に効果的に関与し、新技術を活用し、世界のがん患者の進化するニーズに対応することができます。

市場力学：急速に進化するがん生物学的療法市場における主要な市場洞察の解明

がん生物学的療法市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • ヘルスケア支出の増加に伴うがんの有病率の増加
  • がん生物学的療法の利点に関する意識の高まり
  • がん治療に対する政府の好意的な政策
• 市場抑制要因
  • 資本集約的な治療
• 市場機会
  • がん生物学的製剤における継続的な技術進歩
  • 効率的ながん生物学的療法の開発に向けた研究開発の活発化
• 市場の課題
  • 抗がん剤治療の影響

ポーターの5つの力：がん生物学的療法市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：がん生物学的療法市場における外部からの影響の把握

外部マクロ環境要因は、がん生物学的療法市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析がん生物学的療法市場における競合情勢の把握

がん生物学的療法市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的な意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスがん生物学的療法市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、がん生物学的療法市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨がん生物学的療法市場における成功への道筋を描く

がん生物学的療法市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • ヘルスケア費の増加に伴いがんの罹患率も増加
    • がん生物学的療法の利点に関する認識の向上
    • がん治療に対する政府の好意的な政策
  • 抑制要因
    • 資本集約的な治療
  • 機会
    • がん生物学的製剤における継続的な技術進歩
    • 効果的ながん生物学的治療法の開発に向けた研究開発活動の活発化
  • 課題
    • 抗がん剤治療の予想される効果
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 がん生物学的療法市場：製品別

• がん増殖抑制剤
• モノクローナル抗体
• ワクチン

第7章 がん生物学的療法市場：投与経路別

• 筋肉内
• 静脈内
• 皮下

第8章 がん生物学的療法市場：エンドユーザー別

• 病院
• 専門センター

第9章 南北アメリカのがん生物学的療法市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域のがん生物学的療法市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカのがん生物学的療法市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• AbbVie, Inc
• Amgen Inc.
• Astellas Pharma Inc.
• AstraZeneca PLC
• Bausch Health Companies Inc.
• Bayer AG
• Biogen Inc.
• bluebird bio, Inc.
• Bristol-Myers Squibb Company
• Eisai Co., Ltd.
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd
• Gilead Sciences, Inc.
• GlaxoSmithKline PLC
• Hikma Pharmaceuticals PLC
• Incyte Corp
• Johnson & Johnson Services, Inc,
• Merck & Co., Inc.
• Novartis AG
• Otsuka Pharmaceutical Co., Ltd
• Pfizer Inc.
• Sanofi SA
• Spectrum Pharmaceuticals, Inc.
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd

LIST OF FIGURES

• FIGURE 1. CANCER BIOLOGICAL THERAPY MARKET RESEARCH PROCESS
• FIGURE 2. CANCER BIOLOGICAL THERAPY MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. CANCER BIOLOGICAL THERAPY MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. CANCER BIOLOGICAL THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. CANCER BIOLOGICAL THERAPY MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. CANCER BIOLOGICAL THERAPY MARKET DYNAMICS
• TABLE 7. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY CANCER GROWTH BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 19. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 22. ARGENTINA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 23. ARGENTINA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 24. ARGENTINA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 25. BRAZIL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 26. BRAZIL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 27. BRAZIL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 28. CANADA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 29. CANADA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 30. CANADA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 31. MEXICO CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 32. MEXICO CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 33. MEXICO CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 34. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 35. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 36. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 38. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 39. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 40. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 42. AUSTRALIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 43. AUSTRALIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 44. AUSTRALIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 45. CHINA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 46. CHINA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 47. CHINA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 48. INDIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 49. INDIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 50. INDIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 51. INDONESIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 52. INDONESIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 53. INDONESIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 54. JAPAN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 55. JAPAN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 56. JAPAN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 57. MALAYSIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 58. MALAYSIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 59. MALAYSIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 60. PHILIPPINES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 61. PHILIPPINES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 62. PHILIPPINES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 63. SINGAPORE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 64. SINGAPORE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 65. SINGAPORE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 66. SOUTH KOREA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 67. SOUTH KOREA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 68. SOUTH KOREA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 69. TAIWAN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 70. TAIWAN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 71. TAIWAN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 72. THAILAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 73. THAILAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 74. THAILAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 75. VIETNAM CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 76. VIETNAM CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 77. VIETNAM CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 78. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 79. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 80. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 82. DENMARK CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 83. DENMARK CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 84. DENMARK CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 85. EGYPT CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 86. EGYPT CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 87. EGYPT CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 88. FINLAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 89. FINLAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 90. FINLAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 91. FRANCE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 92. FRANCE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 93. FRANCE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 94. GERMANY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 95. GERMANY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 96. GERMANY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 97. ISRAEL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 98. ISRAEL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 99. ISRAEL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 100. ITALY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 101. ITALY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 102. ITALY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 103. NETHERLANDS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 104. NETHERLANDS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 105. NETHERLANDS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 106. NIGERIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 107. NIGERIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 108. NIGERIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 109. NORWAY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 110. NORWAY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 111. NORWAY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 112. POLAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 113. POLAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 114. POLAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 115. QATAR CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 116. QATAR CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 117. QATAR CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 118. RUSSIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 119. RUSSIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 120. RUSSIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 121. SAUDI ARABIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 122. SAUDI ARABIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 123. SAUDI ARABIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 124. SOUTH AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 125. SOUTH AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 127. SPAIN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 128. SPAIN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 129. SPAIN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 130. SWEDEN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 131. SWEDEN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 132. SWEDEN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 133. SWITZERLAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 134. SWITZERLAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 135. SWITZERLAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 136. TURKEY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 137. TURKEY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 138. TURKEY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 139. UNITED ARAB EMIRATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 140. UNITED ARAB EMIRATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 141. UNITED ARAB EMIRATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 142. UNITED KINGDOM CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 143. UNITED KINGDOM CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 144. UNITED KINGDOM CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 145. CANCER BIOLOGICAL THERAPY MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 146. CANCER BIOLOGICAL THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

The Cancer Biological Therapy Market was valued at USD 64.95 billion in 2023, expected to reach USD 72.42 billion in 2024, and is projected to grow at a CAGR of 11.60%, to USD 140.04 billion by 2030.

Cancer biological therapy, often known as immunotherapy, leverages the body's immune system to target and combat cancer cells, encompassing various modalities like monoclonal antibodies, vaccines, and cytokine therapies. As the incidence of cancer continues to rise, there is an increasing necessity for innovative treatments that offer fewer side effects than traditional methods like chemotherapy and radiation. This biologically diverse therapeutic approach has significant applications across numerous cancer types, including melanoma, breast cancer, and leukemia, to name a few. The end-use scope primarily includes hospitals, specialized cancer treatment centers, and research institutes, where tailored biological therapies can be developed based on patient-specific cancer profiles.

Market growth is largely influenced by technological advancements in biotechnology and a deeper understanding of cancer genomics, alongside an expanding pipeline of biologics and increasing regulatory approvals. The potential opportunities lie in the rising demand for personalized medicine and the rapid development of new therapies addressing previously hard-to-treat cancers. To capitalize on this, companies should invest in R&D for next-generation antibody-drug conjugates and cell-based immunotherapies. However, the market faces challenges such as high treatment costs, complex manufacturing processes, and stringent regulatory requirements that can delay commercialization.

Innovation can be driven by enhancing drug delivery systems to improve efficacy and patient convenience, and exploring the use of artificial intelligence for personalized treatment regimens. Collaborations with research institutions to develop biosimilars and novel biomarkers could further propel market growth. The market remains dynamic, marked by continuous breakthroughs but requires companies to navigate regulatory landscapes adeptly and manage cost barriers to maintain competitiveness. By focusing on these strategies, businesses can effectively engage with emerging trends, leverage new technologies, and address the evolving needs of cancer patients globally.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cancer Biological Therapy Market

The Cancer Biological Therapy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Growing prevalence of cancer with increased healthcare expenditure
  • Increasing awareness regarding benefits of cancer biological therapy
  • Favorable government policies for cancer based therapies
• Market Restraints
  • Capital intensive treatment
• Market Opportunities
  • Ongoing technological advancements in cancer biologics
  • Rising research and development activities for development of efficient cancer biological therapies
• Market Challenges
  • Probable effects of anti-cancer drug therapy

Porter's Five Forces: A Strategic Tool for Navigating the Cancer Biological Therapy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cancer Biological Therapy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cancer Biological Therapy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cancer Biological Therapy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cancer Biological Therapy Market

A detailed market share analysis in the Cancer Biological Therapy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cancer Biological Therapy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cancer Biological Therapy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cancer Biological Therapy Market

A strategic analysis of the Cancer Biological Therapy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cancer Biological Therapy Market, highlighting leading vendors and their innovative profiles. These include AbbVie, Inc, Amgen Inc., Astellas Pharma Inc., AstraZeneca PLC, Bausch Health Companies Inc., Bayer AG, Biogen Inc., bluebird bio, Inc., Bristol-Myers Squibb Company, Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Gilead Sciences, Inc., GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, Incyte Corp, Johnson & Johnson Services, Inc,, Merck & Co., Inc., Novartis AG, Otsuka Pharmaceutical Co., Ltd, Pfizer Inc., Sanofi SA, Spectrum Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd.

Market Segmentation & Coverage

This research report categorizes the Cancer Biological Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product, market is studied across Cancer Growth Blockers, Monoclonal Antibodies, and Vaccines.
• Based on Route of Administration, market is studied across Intramuscular, Intravenous, and Subcutaneous.
• Based on End-Users, market is studied across Hospitals and Specialty Centers.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing prevalence of cancer with increased healthcare expenditure
    • 5.1.1.2. Increasing awareness regarding benefits of cancer biological therapy
    • 5.1.1.3. Favorable government policies for cancer based therapies
  • 5.1.2. Restraints
    • 5.1.2.1. Capital intensive treatment
  • 5.1.3. Opportunities
    • 5.1.3.1. Ongoing technological advancements in cancer biologics
    • 5.1.3.2. Rising research and development activities for development of efficient cancer biological therapies
  • 5.1.4. Challenges
    • 5.1.4.1. Probable effects of anti-cancer drug therapy
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Cancer Biological Therapy Market, by Product

• 6.1. Introduction
• 6.2. Cancer Growth Blockers
• 6.3. Monoclonal Antibodies
• 6.4. Vaccines

7. Cancer Biological Therapy Market, by Route of Administration

• 7.1. Introduction
• 7.2. Intramuscular
• 7.3. Intravenous
• 7.4. Subcutaneous

8. Cancer Biological Therapy Market, by End-Users

• 8.1. Introduction
• 8.2. Hospitals
• 8.3. Specialty Centers

9. Americas Cancer Biological Therapy Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Cancer Biological Therapy Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Cancer Biological Therapy Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie, Inc
• 2. Amgen Inc.
• 3. Astellas Pharma Inc.
• 4. AstraZeneca PLC
• 5. Bausch Health Companies Inc.
• 6. Bayer AG
• 7. Biogen Inc.
• 8. bluebird bio, Inc.
• 9. Bristol-Myers Squibb Company
• 10. Eisai Co., Ltd.
• 11. Eli Lilly and Company
• 12. F. Hoffmann-La Roche Ltd
• 13. Gilead Sciences, Inc.
• 14. GlaxoSmithKline PLC
• 15. Hikma Pharmaceuticals PLC
• 16. Incyte Corp
• 17. Johnson & Johnson Services, Inc,
• 18. Merck & Co., Inc.
• 19. Novartis AG
• 20. Otsuka Pharmaceutical Co., Ltd
• 21. Pfizer Inc.
• 22. Sanofi SA
• 23. Spectrum Pharmaceuticals, Inc.
• 24. Takeda Pharmaceutical Company Limited
• 25. Teva Pharmaceutical Industries Ltd